glaucoma type 1C

disease
On this page

Also known as glaucoma 1, primary open angle, Cglaucoma 1C, primary open angleGLC1C

Summary

glaucoma type 1C (MONDO:0011129) is a disease. A subtype of open-angle glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameglaucoma type 1C
Mondo IDMONDO:0011129
OMIM601682
UMLSC1866483
MedGen356544
GARD0002484
Is cancer (heuristic)no

Also known as: glaucoma 1, primary open angle, C · glaucoma 1C, primary open angle · GLC1C

Disease family

This is a subtype of open-angle glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye disorderglaucomaopen-angle glaucomaglaucoma type 1C

Related subtypes (6): residual stage of open angle glaucoma, low tension glaucoma, glaucoma 1, open angle, P, glaucoma 1, open angle, O, juvenile open angle glaucoma, OPTN-related open angle glaucoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.